GNI-EPS Pharmaceuticals

GNI-EPS Pharmaceuticals is a joint venture between the Japanese biotechnology firm GNI Group and the Japanese contract research organization EPS Holdings, primarily operating in China. The company focuses on the clinical development and commercialization of innovative therapies for organ fibrosis and liver diseases. Its lead candidate, F351 (Hydronidone), is a next-generation anti-fibrotic small molecule that has successfully met its primary endpoint in a pivotal Phase 3 trial for HBV-induced liver fibrosis in China. Additionally, the company is advancing F573, a pan-caspase inhibitor for acute liver failure, and manages the clinical expansion of Pirfenidone (Etuary) into new indications such as systemic sclerosis-associated interstitial lung disease. GNI-EPS leverages GNI's proprietary gene network analysis platform and EPS's extensive clinical research capabilities to address high-prevalence diseases in the Asian market.